Post-earnings recap
Reported
Wed, Oct 27, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioMarin's earnings report indicates a challenging quarter, particularly with the EPS miss. The stock's decline of 2.32% reflects investor concerns over the lack of guidance and the company's current financial performance. Investors will be watching closely for updates on clinical trials and product developments in the coming months.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | -72.41% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach regarding future performance. They emphasized the importance of their clinical pipeline but did not offer specific projections.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing clinical trials and product development.